J&J polishes up its new list of late-stage blockbuster candidates — and cancer remains big
J&J’s R&D group at Janssen has always kept its eyes on the blockbuster prize with a regular look at its top prospects in the pipeline. Now — after some failures and approvals — it’s offered up its latest roster of 10 top candidates for $1 billion-plus in revenue with potential approvals through the next 4 years. And there are some new drugs mixed in with some old favorites.
In a day-long business review on Wednesday, R&D chief Mathai Mammen spotlighted these 10 drugs as their most promising programs
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.